Most Favored Nation Pricing and Affordability of GLP-1RAs for Obesity Treatment in Medicare

Key Points

• The evaluation aims to analyze the 10-year pricing and affordability of GLP-1RAs for obesity under Medicare.
• Economic evaluation over a 10-year period
• Focus on glucagon-like peptide-1 receptor agonists
• Assess impact on affordability in Medicare
• Findings indicate potential barriers to access due to pricing
• Affordability issues highlighted for long-term obesity treatment
• Economic implications suggest necessary pricing reforms for better access